Cangene Corporation (Cangene) is a biopharmaceutical company in the business of developing, manufacturing, and commercializing products and technologies for global markets. It operates in two segments: biopharmaceutical operations and contract services. The biopharmaceutical operations segment consist of sales of approved products and non- specialty plasma. The contract-services segment consists of third-party contract-manufacturing revenues at the Company's Winnipeg facilities, as well as at Cangene bioPharma in Baltimore. It also provides commercial contract-manufacturing services, primarily through a United States-based subsidiary. The Company's products include Rho(D) Immune Globulin (Human) for Injection (WinRho) SDF, Hepatitis B Immune Globulin (Human) Injection (HepaGam B) and Varicella Zoster Immune Globulin (Human) (VariZIG). In February 2014, Emergent BioSolutions Inc completed the acquisition of Cangene.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
WebN/A
Phone+1-204-2754200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Cangene (TSE:CNJ) Frequently Asked Questions
What is Cangene's stock symbol?
Cangene trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CNJ."
Has Cangene been receiving favorable news coverage?
News stories about CNJ stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cangene earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cangene.
Who are Cangene's key executives?
Cangene's management team includes the folowing people:
- R. Craig Baxter, Chairman of the Board
- John A. Sedor, President, Chief Executive Officer, Director (Age 72)
- Jeffrey Lamothe, Chief Financial Officer
- Gary Clyde Floyd, Chief Operating Officer
- Laura Saward, Chief Scientific Officer
- Michael D. Adelman, Vice President - Commercial Operations
- Francis St. Hilaire, Vice President, General Counsel, Secretary
- Les Deezar, Vice President - Human Resources
- Chris Sinclair, Vice President - Strategic Planning
- Kevin G. Taylor, Vice President - Business Development
How do I buy shares of Cangene?
Shares of CNJ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How can I contact Cangene?
Cangene's mailing address is 155 Innovation Dr, WINNIPEG, MB R3T 5Y3, Canada. The biopharmaceutical company can be reached via phone at +1-204-2754200.
MarketBeat Community Rating for Cangene (TSE CNJ)
MarketBeat's community ratings are surveys of what our community members think about Cangene and other stocks. Vote "Outperform" if you believe CNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
